We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Smartphone-Powered Microfluidic ‘Lab on a Strip’ Dengue Test More Powerful Than LFT Testing

By LabMedica International staff writers
Posted on 11 Apr 2022

Dengue fever affects an estimated 400 million people each year. While most cases are mild, dengue infections can lead to significant complications and can be fatal. Dengue can be most severe in children and is a serious health challenge facing half the global population. Now, new ‘lab on a strip’ technology has shown the capability of smartphone-powered tests for dengue fever.

Biomedical technology researchers from the University of Reading (London, UK) have developed the new diagnostic test for research that uses ‘lab on a strip’ technology, which performs 10 or more tests a very small amount of liquid sample (such as blood, urine or saliva). The researchers used a new diagnostic kit called Cygnus to detect dengue fever with significantly improved rates over lateral flow testing kits.

The team trialled the tests alongside already established alternatives and found the new tests showed 82% clinical sensitivity, beating lateral flow testing (74% sensitivity) and matching hospital-based lab diagnostics (83% sensitivity). At the same time, these devices make 10 measurements allowing us to identify which of the four different dengue virus types caused the infection.

“The paper shows exciting potential for the use of the microfluidic ‘lab on a strip’ tests that can be used in conjunction with a smartphone and are more powerful than LFT testing in this case,” said Dr. Sarah Needs, Postdoctoral Research Associate in Microfluidic Antimicrobial Resistance Testing from the University of Reading. “As well as being cheap to produce, the lab on a strip technology allows users to test many different targets at once in one single sample, so it could be useful to detect multiple diseases not just one.”

“While some people might only recently learned of the trade-offs between home vs. lab testing following COVID-19, in many parts of the world rapid lateral flow tests are used for a range of illnesses including dengue,” added Dr. Alexander Edwards, Associate Professor in Biomedical Technology at the University of Reading co-created the lab on a strip technology. “With the Cygnus concept, we are tackling the biggest hurdle for home testing. How do you make something portable that can be cheaply mass produced while still matching laboratory test performance? By designing the microfluidic lab on a strip using mass-production melt-extrusion it is possible to scale up production and produce hundreds of thousands of tests. By recording results with smartphones, which are becoming ubiquitous, we have designed something that could be revolutionary for healthcare.”

Related Links:
University of Reading 

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Myeloperoxidase Assay
IDK MPO ELISA
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.